-
Patent Agency Ranking
公开(公告)号：US20240092918A1
公开(公告)日：2024-03-21
申请号：US18164519
申请日：2023-02-03
Applicant: Novartis AG
Inventor： Steven BENDER , Tracy CHARLTON , Anna GALKIN , Bernhard Hubert GEIERSTANGER , Scott Martin GLASER , Shailaja KASIBHATLA , Mark KNUTH , Sabine ROTTMANN , Sarah RUE , Glen SPRAGGON , Tetsuo UNO
CPC classification number: C07K16/2866 , A61K47/6803 , A61K47/6849 , A61P35/00 , A61K2039/505
Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
公开(公告)号：US20230053449A1
公开(公告)日：2023-02-23
申请号：US17289058
申请日：2019-10-30
Applicant: NOVARTIS AG
Inventor： Lisa BARNETT , Steven BENDER , Alex Cortez , Sarah COX , Jonathan DEANE , Scott Martin GLASER , Ben WEN , Tom Yao-Hsiang WU
Abstract: Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.
-
3.发明公开公开(公告)号：US20240336701A1
公开(公告)日：2024-10-10
申请号：US18427264
申请日：2024-01-30
Applicant: Novartis AG
Inventor： Michael DIDONATO , Christoph ERKEL , Anna Galkin , Scott Martin GLASER , Klaus Felix HARTLEPP , Yong JIA , Alexandra KRAUS , Christian Cho-Hua LEE , Sarah Michelle RUE , Jian SHI , Xenia Karola WEZLER
CPC classification number: C07K16/40 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61P35/00 , C07K16/2818 , A61K2039/505 , A61K2039/507 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/92
Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
-
公开(公告)号：US20210170043A1
公开(公告)日：2021-06-10
申请号：US16669291
申请日：2019-10-30
Applicant: NOVARTIS AG , ADURO BIOTECH, INC.
Inventor： Lisa BARNETT , Steven BENDER , Charles Y. CHO , Sarah COX , Jonathan Deane , Scott Martin GLASER , Xueshi Hao , Shailaja KASIBHATLA , Weijia OU , Tetsuo UNO , Yongqin WAN , Ben WEN , Tom Yao-Hsiang WU
IPC: A61K47/68 , C07K16/28 , A61K31/688 , A61P35/00
Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.
-
公开(公告)号：US20200216548A1
公开(公告)日：2020-07-09
申请号：US16482173
申请日：2018-02-01
Applicant: NOVARTIS AG
Inventor： Steven BENDER , Tracy CHARLTON , Anna GALKIN , Bernhard Hubert GEIERSTANGER , Scott Martin GLASER , Shailaja KASIBHATLA , Mark KNUTH , Sabine ROTTMANN , Sarah RUE , Glen SPRAGGON , Tetsuo UNO
Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
-
-
-
Search Results
5
records
(took 0.01 seconds)
